Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis.

A multi-country study by Simpson-Yap et al., published as a pre-print, which included 2,340 MS patients with SARS-CoV-2 infection, identified an increased risk for hospitalization, ICU admission, and ventilator use with rituximab (OR, 2.43; 95% CI, 1.48–4.02; OR, 3.93; 95% CI, 1.56–9.89; OR, 4.00; 95% CI, 1.54–10.39, respectively) and an increased risk for hospitalization with ocrelizumab (OR, 1.56; 95% CI:, 1.01–2.41), when compared to dimethyl fumarate; the risk for ICU admission with ocrelizumab was nearly significant (OR, 2.30; 95%, 0.98–5.39).

also in 3,287 other papers